Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 14/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 12/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7570714 | 0.93 | ADRB3 (0.49) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7094896 | 0.92 | ADRB3 (0.51) | ADRB3ADRB1ADRB2MAPTPSMB5 | |
| Formic Acid SCHEMBL7090770 | 0.91 | ADRB3 (0.49) | ADRB3ADRB1ADRB2PSMB5 | |
| SCHEMBL7094732 | 0.88 | ADRB3 (0.69) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7091815 | 0.84 | ADRB3 (0.76) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7091284 | 0.83 | ADRB3 (0.64) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7096101 | 0.82 | ADRB3 (0.64) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7095222 | 0.82 | ADRB3 (0.77) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7096321 | 0.81 | ADRB3 (0.65) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7096323 | 0.81 | ADRB1 (0.64) | ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | ADRB3 3/4885ADRB1 2/4885ADRB2 1/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | ADRB3 2/4885ADRB1 1/4885ADRB2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.